SERUM TUMOUR NECROSIS FACTOR-α AND TRANSFORMING GROWTH FACTOR-β LEVELS IN CHRONIC HEPATITIS C PATIENTS ARE IMMUNOMODULATED BY THERAPY
- 31 January 2002
- journal article
- clinical trial
- Published by Elsevier BV in Cytokine
- Vol. 17 (2), 108-117
- https://doi.org/10.1006/cyto.2001.0997
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis CClinical Biochemistry, 2001
- Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis CHepatology, 2001
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy dataClinical Pharmacology & Therapeutics, 2000
- A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis CHepatology, 2000
- Predictors of sustained response to alpha interferon therapy in chronic hepatitis CClinical Biochemistry, 1999
- Type I Interferons Keep Activated T Cells AliveThe Journal of Experimental Medicine, 1999
- Role of early cytokines, including alpha and beta interferons (IFN-α\β), in innate and adaptive immune responses to viral infectionsSeminars in Immunology, 1998
- Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjectsClinical Pharmacology & Therapeutics, 1996